We rank companies based on fund manager, research analyst and news sentiment
ACRS stock icon

Aclaris Therapeutics, Inc.
ACRS

$1.21
0%
 

About: Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.

Employees: 91

0
Funds holding %
of 6,474 funds
0
Analysts bullish %
of 4 analysts
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

48% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 27

10% less call options, than puts

Call options by funds: $52.6K | Put options by funds: $58.7K

16.33% less ownership

Funds ownership: 98.84% [Q3] → 82.51% (-16.33%) [Q4]

23% less funds holding

Funds holding: 137 [Q3] → 105 (-32) [Q4]

59% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 54

87% less capital invested

Capital invested by funds: $480M [Q3] → $61.4M (-$419M) [Q4]

100% less funds holding in top 10

Funds holding in top 10: 4 [Q3] → 0 (-4) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$1
17%
downside
Avg. target
$5.25
334%
upside
High target
$9
644%
upside

4 analyst ratings

positive
50%
neutral
50%
negative
0%
HC Wainwright & Co.
Raghuram Selvaraju
644%upside
$9
Buy
Reiterated
29 Dec 2023
Stifel
Alex Thompson
17%downside
$1
Hold
Maintained
18 Dec 2023
HC Wainwright & Co.
Raghuram Selvaraju
644%upside
$9
Buy
Maintained
14 Nov 2023
Stifel
Alex Thompson
65%upside
$2
Hold
Downgraded
13 Nov 2023

Financial journalist opinion